What the Study Found (In Plain English)
Published in Nutricion hospitalaria (2021), this phase iii randomized trial evaluating 73 human participants investigated: Introduction: a lipid emulsion (LE) may result in different immunomodulatory effects depending on its fatty acid composition. Key clinical takeaway: There were no statistically significant differences in the occurrence of adverse effects either. Conclusions: in our study, SMOFlipid® proved to be non-inferior to Clinoleic® in terms of efficacy and safety.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Nutricion hospitalaria, 2021-02-23; N = 73; Rigor 82/100): There were no statistically significant differences in the occurrence of adverse effects either. Conclusions: in our study, SMOFlipid® proved to be non-inferior to Clinoleic® in terms of efficacy and safety.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.